Nephron Research LLC
Nephron Research LLC
Nephron Research: Myriad Genetics (MYGN) PRIME Care Study KOL Call w/ Dr. Charlie Nemeroff
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Myriad published the results of the PRIME Care Study on Tuesday afternoon in JAMA. In the 2K patient study, GeneSight was successful on both of the co-primary endpoints. Despite the rosy headlines, the devil is always in the details! Such was the case with the GUIDED Study published in 2019.
To help pick through the results, Nephron hosted a Q&A call with the leading KOL in the category of pharmacogenetics: Dr. Charlie Nemeroff. Topics of discussion included a review of the PRIME Care study, the pros and cons of the data, implications for clinical adoption of the test and payor coverage, and thoughts on the regulatory environment for pharmacogenetic testing. The primary company in focus wasMyriad Genetics (MYGN).